Supply-side risk adjustment and outlier payment policy by Mougeot, Michel & Naegelen, Florence
Combined deletion of cathepsin protease
family members reveals compensatory
mechanisms in cancer
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Proteases are important for regulating multiple tumorigenic processes, including angiogenesis, tumor growth, and
invasion. Elevated protease expression is associated with poor patient prognosis across numerous tumor types.
Several multigene protease families have been implicated in cancer, including cysteine cathepsins. However,
whether individual family members have unique roles or are functionally redundant remains poorly understood.
Here we demonstrate stage-dependent effects of simultaneously deleting cathepsin B (CtsB) and CtsS in a murine
pancreatic neuroendocrine tumor model. Early in tumorigenesis, the double knockout results in an additive re-
duction in angiogenic switching, whereas at late stages, several tumorigenic phenotypes are unexpectedly restored
to wild-type levels. We identified CtsZ, which is predominantly supplied by tumor-associated macrophages, as the
compensatory protease that regulates the acquired tumor-promoting functions of lesions deficient in both CtsB and
CtsS. Thus, deletion of multiple cathepsins can lead to stage-dependent, compensatory mechanisms in the tumor
microenvironment, which has potential implications for the clinical consideration of selective versus pan-family
cathepsin inhibitors in cancer.
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Proteases play critical roles in numerous processes essen-
tial for normal function in multicellular organisms, and
thus proteolysis is highly regulated to avoid aberrant acti-
vation and tissue destruction. However, proteases can fre-
quently be dysregulated in cancer as a consequence of
increases in mRNA or protein expression, decreased ex-
pression of their endogenous inhibitors, or alterations in
subcellular localization, among other mechanisms (Lo-
pez-Otin and Bond 2008; Sevenich and Joyce 2014). It
has also become evident that these enzymes can be regu-
lated at a network level (Mason and Joyce 2011) in which
proteases and their endogenous inhibitors and activators
are integrated within a complex interconnected “protease
web,” a concept proposed by Overall and colleagues (auf
dem Keller et al. 2007; Fortelny et al. 2014).
In recent years, one of themost intensively studied fam-
ilies of proteases in cancer has been the cysteine cathepsin
proteases (Olson and Joyce 2015) or cathepsins as we refer
to them here. The cathepsin family is comprised of 11
members in humans: cathepsin B (CtsB), CtsC, CtsH,
CtsF, CtsK, CtsL, CtsO, CtsS, CtsL2/V, CtsW, and
CtsX/Z (Shi et al. 1992; Cao et al. 1994; Santamaria
et al. 1998; Deussing et al. 2000; Turk et al. 2012). CtsX/Z
has been referred to by both names following its identifi-
cation and characterization (Nagler and Menard 1998;
Santamaria et al. 1998; Nagler et al. 1999; Deussing
et al. 2000); however, as the official gene name for this en-
zyme is CtsZ, we refer to it using this nomenclature
throughout. Increased expression and activity of individu-
al cathepsin family members has been reported in multi-
ple cancers and generally correlates with poor patient
prognosis (Jedeszko and Sloane 2004; Mohamed and
Sloane 2006). Important insights into the regulatory func-
tions of cathepsins in cancer have come from a number
of genetically engineered mouse models, including
the RIP1-Tag2 (RT2) pancreatic neuroendocrine tumor
(PanNET) model, the MMTV-PyMT model of mammary
tumorigenesis and lung metastasis, the K14-HPV16
squamous cell carcinoma model, and the KPC model of
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pancreatic ductal adenocarcinoma (Gocheva et al. 2006,
2010a; Vasiljeva et al. 2006, 2008; Wang et al. 2006; Den-
nemarker et al. 2010; Sevenich et al. 2010; Gopinathan
et al. 2012; Ruffell et al. 2013; Akkari et al. 2014; for re-
view, see Olson and Joyce 2015).
Expression of six of the 11 cathepsins (CtsB, CtsC,
CtsH, CtsL, CtsS, and CtsZ) is up-regulated in the
multistage RT2 model as PanNET lesions progress from
hyperplastic and angiogenic islet precursors to end-stage
invasive tumors (Joyce et al. 2004). While cancer cells pro-
duce a subset of these cathepsins, tumor-associated mac-
rophages (TAMs) are the major source of these enzymes
in the PanNET microenvironment (Gocheva et al. 2006,
2010a,b; Wang and Joyce 2010; Akkari et al. 2014). The
number of TAMs increases with tumor progression in
both human and murine PanNETs (Gocheva et al.
2010b; Pyonteck et al. 2012), and TAMs have critical roles
in promoting essential hallmark capabilities of cancer, in-
cluding tumor angiogenesis, invasion, and metastasis
(Qian and Pollard 2010; Quail and Joyce 2013).
In the RT2 PanNET model, bone marrow transplanta-
tion experiments demonstrated that TAM-derived CtsB
and CtsS were either predominantly or exclusively re-
sponsible for the growth-promoting and invasive func-
tions of these cathepsins (Gocheva et al. 2010b). The
tumorigenic functions of CtsZ were derived from both
the cancer cell and TAM compartments (Akkari et al.
2014). We showed that the proteolytic activities of CtsB
and CtsS drive the dissolution of cell–cell junctions and
extracellular matrix degradation in the RT2 model, while
CtsZ acts in a proteolytically independent manner by reg-
ulating interactions with components of the extracellular
matrix (Gocheva et al. 2006; 2010b; Akkari et al. 2014).
We performed a comprehensive series of genetic exper-
iments to individually delete each of the six up-regulated
cathepsins in the RT2 model. We identified both unique
and shared roles in promoting PanNET malignancy with-
out evident compensatory mechanisms by other cathep-
sin family members (Gocheva et al. 2006, 2010a,b;
Gocheva and Joyce 2007; Akkari et al. 2014). Given that
multiple cathepsins have been shown to have tumor-pro-
moting functions in RT2 mice, here we investigated
whether combined deletion of individual familymembers
would enhance these effects or rather cause alterations to
the protease web that may result in unexpected pheno-
types. These are important questions to address for under-
standing not only the unique versus overlapping functions
of multigene family members but also the translational
implications of using selective versus pan-family cathep-
sin inhibitors in cancer.
Results
Combined deletion of CtsB and CtsS reduces
angiogenic switching
We reported previously the pronounced effects of individ-
ual CtsB or CtsS deletion in blocking multiple aspects of
PanNET development and progression (summarized in
Table 1; Gocheva et al. 2006). To investigate whether
there are additive effects of simultaneously deleting these
tumor-promoting cathepsins, we generated CtsB−/−S−/−
double-knockoutRT2mice.We first analyzed the number
of angiogenic islets at 10.5 wk as an indication of the abil-
ity of premalignant lesions to induce neovascularization,
which is required for subsequent tumor development
and growth (Parangi et al. 1995). This revealed a more pro-
nounced 60% reduction in angiogenic switching in the
CtsB−/−S−/− RT2 mice (Fig. 1A) compared with the 24%
reduction in eitherCtsB- orCtsS-null RT2 animals (Table
1), suggesting an additive effect of combined CtsB and
CtsS deletion on this early rate-limiting step inmultistage
tumorigenesis.
A separate cohort of CtsB−/−S−/− RT2 mice was ana-
lyzed at the end-stage time point of 13.5 wk, in which
we found a significant reduction in both tumor number
and tumor volume compared with wild-type RT2 animals
(Fig. 1B,C). However, deletion of both cathepsins did not
result in additional impairment of overall tumor burden
compared with the individual CtsB−/− or CtsS−/− RT2
mice (Table 1), in contrast to the additive effect of com-
bined deletion on angiogenic switching at 10.5 wk. Simi-
larly, no further differences in tumor volume or tumor
number were observed in CtsB+/−S+/− RT2 animals (Sup-
plemental Fig. S1A,B) compared with the homozygous
deletion of either cathepsin.
Table 1. Comparative analyses of multiple tumorigenic processes in the RT2 genotypes listed at the top of each column
B−/− RT2 S−/− RT2 B−/−S−/− RT2 B+/−S+/− RT2 Z−/− RT2 B−/−S−/−Z−/− RT2 B+/−S+/−Z+/− RT2
Angiogenic
switching
24% ↓ 24% ↓ 60% ↓ — 53% ↓ — —
Tumor volume 72% ↓ 47% ↓ 51% ↓ 39% ↓ 63% ↓ 58% ↓ 45% ↓
Tumor number 48% ↓ 17% ↓ 36% ↓ 42% ↓ No change 53% ↓ 45% ↓
Proliferation 44% ↓ No change 85% ↓ No change 86% ↓ 53% ↓ No change
Apoptosis 2.3-fold ↑ 1.6-fold ↑ No change No change 1.8-fold ↑ 3.8-fold ↑ 4.6-fold ↑
Tumor
vascularization
56% ↓ 48% ↓ No change 42% ↓ No change 73% ↓ No change
Invasion Reduced Reduced No change No change Reduced Reduced No change
All analyses were performed by comparison with wild-type RT2 controls, and the percentage differences, fold changes, and invasion
grading are all indicated relative to wild-type RT2 animals.
Data were compiled from Gocheva et al. (2006), Akkari et al. (2014), and this study.
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CtsB−/−S−/− RT2 mice show no difference in tumor
invasion, vascularization, or apoptosis compared with
wild-type RT2 animals
Characterization of several key tumorigenic properties re-
vealed that while cancer cell proliferationwas impaired in
CtsB−/−S−/− 13.5-wk tumors (Fig. 1D; Supplemental Fig.
S1C), apoptosis levels were not significantly altered (Sup-
plemental Fig. S1D). This is in contrast to both the single
CtsB−/− and CtsS−/− tumors, where a significant increase
in apoptosis was observed (Table 1). Similarly, analysis of
the spectrum of invasive tumors showed no significant
difference between CtsB−/−S−/− and wild-type RT2 mice
(Fig. 1E; Supplemental Fig. S1E), while the single deletion
of these genes resulted in a marked impairment in inva-
sion (Table 1; Gocheva et al. 2006). Finally, analysis of a
panel of vascular parameters, including vessel branching,
thickness, length,andpericytecoverage, revealednodiffer-
ences betweenCtsB−/−S−/− andwild-type tumors (Supple-
mental Fig. S1F,G). This result contrastswith the impaired
tumor vascularization in the individual knockouts (Table
1;Gochevaetal.2006)andthesignificantdecreaseinangio-
genic switching observed in CtsB−/−S−/− RT2 animals at
10.5 wk of age (Fig. 1A).
Collectively, these data indicate defined stage-depen-
dent effects of combined CtsB and CtsS deletion on Pan-
NET progression by comparison with either cathepsin
knockout alone. The additive effects observed in the dou-
ble knockouts were restricted to the premalignant stage,
where the number of angiogenic lesions was substantially
decreased by comparison with either cathepsin knockout
alone. In contrast, the subsequent processes of tumor
growth, vascularization, and invasion were either not fur-
ther impaired in CtsB−/−S−/− RT2 mice compared with
single knockouts or, unexpectedly, not altered compared
with wild-type RT2 animals (Table 1).
Figure 1. Simultaneous deletion of CtsB and CtsS reduces angiogenic switching and tumor growth but does not affect tumor invasion.
(A) Angiogenic switching was assessed in 10.5-wk-old wild-type RT2 or CtsB−/−S−/− RT2 mice (n = 10 mice for both genotypes) by man-
ually counting the number of angiogenic islets in the pancreas. The graph shows the average number of angiogenic islets per mouse. (B)
Cumulative tumor volume, represented as the sum of the volumes of all tumors permouse, was calculated for 13.5-wk-old wild-type RT2
(n = 57) and CtsB−/−S−/− RT2 (n = 46) mice. (C ) Graph depicting the average number of tumors per mouse in wild-type and CtsB−/−S−/−
RT2 animals at the 13.5-wk endpoint. The following numbers of animals were analyzed per group: wild-type RT2, n = 52; CtsB−/−S−/−
RT2, n = 37. (D) Quantitation of Ki67+ cells in wild-type andCtsB−/−S−/− RT2 tumors relative to the total number of DAPI+ cells showed
an 85% decrease in cell proliferation in tumors deficient for both CtsB and CtsS. All tumors from five wild-type RT2 and 11 CtsB−/−S−/−
RT2mice were analyzed. (E) Graph showing the proportions of encapsulated, microinvasive (IC1), and invasive (IC2) carcinomas in wild-
type RT2 and CtsB−/−S−/− RT2 mice at 13.5 wk. The following numbers of samples were analyzed: wild-type RT2, 18 mice, 97 tumors;
CtsB−/−S−/− RT2, 14 mice, 68 tumors. The graphs showmean + SEM. Statistical significance was calculated by unpaired two-tailed Stu-
dent’s t-test (A–D) or using a cumulative logit model with generalized estimating equations to correct for correlations within individual
mice (E). (n.s.) Nonsignificant; (∗∗∗) P < 0.001.
Akkari et al.
222 GENES & DEVELOPMENT
Altered protease expression in CtsB−/−S−/− tumors
A concern that is frequently raised in the generation and
analysis of knockouts for members of large gene families
(as for the cathepsins presented here) is that functional
compensation by other family members may occur to
take over the role of the deleted genes, potentially mask-
ing the resultant phenotype. While we have not observed
this phenomenon in previous analyses of individual Cts
mutants in RT2 tumorigenesis (Gocheva et al. 2006,
2010a,b; Akkari et al. 2014), the adaptive selection result-
ing from simultaneously deleting more than one cathep-
sin family member may give rise to conditions that are
more favorable to functional compensation.
As the additive, tumor-limiting phenotype we observed
at the early angiogenic islet stage in CtsB−/−S−/− RT2 tu-
morigenesis is reversed in end-stage lesions, we hypothe-
sized that up-regulation and functional compensation by
another factor, potentially a protease, might specifically
occur later in tumor progression in the absence of both
CtsB and CtsS to paradoxically promote malignancy. To
investigate the potential mediators of this proposed com-
pensation, we analyzed the expression levels of a panel of
proteases and protease inhibitors that have previously
been shown to be critical in cancer progression (Affara
et al. 2009; Shchors et al. 2013; Sevenich and Joyce
2014). Analyses ofmRNAexpression for a panel of cathep-
sins, cathepsin inhibitors, and several matrix metallopro-
teinases (MMPs) were performed in 13.5-wk end-stage
wild-type, CtsB−/−S−/− and CtsB+/−S+/− tumors (Fig. 2A;
Supplemental Fig. S2A,B). This revealed a significant up-
regulation of CtsZ and Mmp13 in CtsB−/−S−/− tumors,
while Mmp3 and Mmp9 expression was down-regulated
(Fig. 2A). The increase in CtsZ expression in CtsB−/−S−/−
tumors was also confirmed at the protein level (Fig. 2B).
Interestingly,CtsZ deletion significantly decreases RT2
tumor invasion (Akkari et al. 2014), whileMmp9 ablation
hasbeen reported tounexpectedlypromote tumor invasion
in two independent PanNETmousemodels (Shchors et al.
2013), including the RT2 model used in this study. Other
MMPs, includingMmp3 andMmp13, have been implicat-
ed in the regulation of tumor development and invasion
(Kessenbrock et al. 2015); however, there have been no cor-
relative studies linking these twoMMPswithPanNETma-
lignancy. In sum, these results suggest that the increase in
CtsZ expression and decrease in Mmp9 expression ob-
served inCtsB−/−S−/− tumorsmay represent compensatory
molecular mechanisms used to promote tumor invasion.
Given the stage-specificity of the effects observed in
CtsB−/−S−/−RT2mice, we hypothesized that the compen-
satory expression changes in the genes identified above
might occur specifically during the transition from angio-
genic islets to neoplastic lesions. Analysis of CtsZ,
Mmp3, and Mmp13 mRNA expression in premalignant
CtsB−/−S−/− angiogenic islets showed no significant dif-
ferences compared with wild-type angiogenic islets (Fig.
2C), while Mmp9 mRNA expression was increased in
CtsB−/−S−/− angiogenic islets compared with wild type
(Fig. 2C). This is in contrast to the differential gene ex-
pression observed between these genotypes in end-stage
tumors (Fig. 2A), suggesting that alterations in the expres-
sion of multiple factors indeed occur late in the course of
CtsB−/−S−/− tumor progression to potentially promote
several tumorigenic processes, including invasion.
CtsZ levels are elevated specifically in CtsB−/−S−/−
RT2 macrophages
We recently identified CtsZ as an important regulator of
PanNET development and malignancy (Akkari et al.
2014). Given that CtsZ is specifically up-regulated during
the transition from angiogenic islets to neoplastic lesions
in CtsB−/−S−/− RT2 animals among the proteases ana-
lyzed above, we subsequently focused on this protease
as a candidate mediator of the compensatory phenotype
inCtsB−/−S−/− tumors. CtsZ is supplied from both cancer
cells and TAMs and promotes tumor invasion through
both intrinsic and extrinsic regulation of cancer cellmotil-
ity (Akkari et al. 2014). We showed previously that infil-
trating TAMs in RT2 tumors predominantly originate
from the bone marrow (Gocheva et al. 2010b). Thus, to
determine the specific cell type responsible for CtsZ
up-regulation in end-stage CtsB−/−S−/− tumors, we first
analyzed CtsZ expression in bonemarrow-derivedmacro-
phages (BMDMs) from tumor-bearing mice. Interestingly,
we found that CtsZ levels were increased in BMDMs
from CtsB−/−S−/− RT2 mice compared with their wild-
type RT2 counterparts (Fig. 2D), while mRNA expression
ofMmp9 andMmp3was down-regulated, andMmp13 did
not change significantly (Supplemental Fig. S2C).
Furthermore, when we sorted cancer cells and TAMs
from wild-type and CtsB−/−S−/− tumors and analyzed
CtsZ expression in each cell population, we found that
onlyTAMs fromCtsB−/−S−/− tumors showed a significant
up-regulation of CtsZ expression, while no differences
were observed in cancer cells (Fig. 2E). Analysis of
Mmp3, Mmp9, and Mmp13 showed no significant differ-
ences in mRNA expression in either cell compartment
(Supplemental Fig. S2D).
We next sought to determine the molecular mecha-
nisms underlying the specific up-regulation of CtsZ in
CtsB−/−S−/− RT2 BMDMs. Comparison of the CtsZ pro-
moter with the promoters of the other cathepsin family
members up-regulated during wild-type RT2 tumorigene-
sis (CtsB, CtsC, CtsH, CtsL, and CtsS) revealed nine tran-
scription factor motifs (TFMs) specific to CtsZ (Fig. 3A,B;
Supplemental Table 1). We focused our interest on one of
these, NFκB, as it is a key orchestrator of innate immunity
and inflammation (Karin 2006). NFκB activity in TAMs
has been shown to regulate and maintain macrophage ac-
tivation and modulate tumor-promoting phenotypes in
response to diverse environmental cues, including stress
signals, inflammatory cytokines, and infection (Karin
and Greten 2005; Hagemann et al. 2008). Interestingly,
we detected a significant increase in nuclear expression
of the NFκB subunit p65 (RelA) in CtsB−/−S−/− RT2
BMDMs compared with their wild-type RT2 counterparts
(Fig. 3C,D).
Together, these results indicate that CtsZ is up-regulat-
ed in BMDMs in CtsB−/−S−/− RT2 mice, potentially via
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Figure 2. Analysis of protease gene expression in CtsB−/−S−/− RT2 tumors identifies macrophage-derived CtsZ as a potential compen-
satory factor. (A) The mRNA expression level of CtsZ,Mmp3,Mmp9, andMmp13 was determined by quantitative PCR (qPCR) in wild-
type RT2 andCtsB−/−S−/− RT2 whole tumors (end-stage, 13.5 wk). This analysis demonstrated increased expression of CtsZ andMmp13
and decreasedMmp3 andMmp9 expression in theCtsB−/−S−/−RT2 tumors. Three to nine independent tumors per genotypewere used for
analysis. (B) Representative protein extracts from wild-type RT2 tumors (n = 5) and CtsB−/−S−/− RT2 tumors (n = 4), at 13.5 wk, were an-
alyzed for CtsZ expression. Actin served as a loading control. Quantification of CtsZ normalized to the loading control using ImageJ soft-
ware showed a significant increase in protein expression in CtsB−/−S−/− RT2 tumors. n = 7 replicate experiments and 31 independent
tumors. (C ) mRNA expression level of CtsZ, Mmp3, Mmp9, and Mmp13 was determined by qPCR in premalignant angiogenic islets
(A.I.) from wild-type RT2 and CtsB−/−S−/− RT2 mice at 10.5 wk of age. No significant changes in expression of CtsZ, Mmp3, or
Mmp13were observed at this early stage of tumorigenesis, whileMmp9 expressionwas increased. Three to five independent sets of pooled
angiogenic islets per genotype. (D) mRNA expression level ofCtsZwas determined by qPCR analysis of bonemarrow-derivedmacrophag-
es (BMDMs) prepared from tumor-bearingwild-type RT2 (n = 3) andCtsB−/−S−/−RT2 (n = 4) animals, which revealed a significant increase
inCtsZ expression inCtsB−/−S−/− RT2 BMDMs. (E) Tumors from wild-type RT2 orCtsB−/−S−/− RT2mice were sorted into a mixed pop-
ulation of live cells (DAPI−), cancer cells (CD45− CD31− F4/80−) or TAMs (CD45+ CD31− F4/80+). Expression of CtsZmRNAwas deter-
mined by qPCR, and the level is depicted relative to the live-cell fraction. Up-regulation of CtsZ expression was found specifically in the
TAM compartment and not in cancer cells. mRNA expression determined by qPCRwas normalized toUbiquitin C for each sample inA
and C–E. Graphs show mean ± SEM. Statistical significance was calculated by unpaired two-tailed Student’s t-test. (n.s.) Nonsignificant;
(∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001.
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increased NFκB nuclear translocation, prior to infiltration
of these cells to the tumor site and their maturation into
TAMs. Therefore, we uncovered a novel compensatory
mechanism that is manifest at the level of normal, non-
cancerous cells in the tumor microenvironment rather
than intrinsic to the cancer cells.
Macrophages accumulate in CtsB−/−S−/− tumors
in association with increased CtsZ expression
and enhanced tumor invasion
To confirm that TAMs are responsible for the overall in-
crease in CtsZ expression, which could potentially pro-
mote tumor invasion, we characterized TAM numbers
and their infiltrative pattern within CtsB−/−S−/− tumors.
Interestingly, immunofluorescence analysis of themacro-
phage marker Iba1 co-stained with CtsZ showed a pro-
nounced TAM accumulation particularly at the invasive
margins of CtsB−/−S−/− tumors compared with wild-type
lesions (Fig. 4A). Quantification of Iba1+ and CtsZ+ cells
throughout whole tumors revealed a 2.0-fold increase
in the number of TAMs and a 2.8-fold increase in CtsZ+
cells in CtsB−/−S−/− tumors compared with wild-type
RT2 tumors (Fig. 4B,C). Analysis of mRNA expression
of Cd68, another macrophage marker, supported the im-
munofluorescence data, showing a significant increase
Figure 3. Analysis of TFMs in the CtsZ promoter reveals a unique NFκBmotif and elevated nuclear p65 levels inCtsB−/−S−/− RT2mac-
rophages. (A) Venn diagram demonstrating the overlap of predicted TFMs present in the CtsZ promoter compared with the CtsB, CtsC,
CtsH,CtsL, andCtsS promoters. There are nine TFMs present in theCtsZ promoter that were not identified in any of these other cathep-
sin family members. Meanwhile, 83 TFMs were present in at least one of the other cathepsins but absent in the CtsZ promoter (see Sup-
plemental Table 1 for a full list of TFMs). (B) TheCtsZ promoter is shown with exons and the 5′ untranslated region (UTR) on the top bar
and nine TFMs listed below. AnNFκB consensus site is highlighted in red upstream of the 5′ UTR. (C ) Wild-type RT2 orCtsB−/−S−/−RT2
BMDMs were subjected to subcellular fractionation, and lysates of the nuclear fraction (top two panels) or cytoplasmic fraction (bottom
two panels) were isolated for immunoblotting of the NFκB subunit p65 and lamin A/C or p65 and actin. Results are representative of n = 3
independent biological replicates. (D) Quantification of p65—normalized to lamin A/C or actin for the nuclear and cytoplasmic fractions,
respectively, using ImageJ software—showed a significant increase in p65 expression in the nucleus of CtsB−/−S−/− RT2 BMDMs. n = 3
replicate experiments. Statistical significance was calculated by unpaired two-tailed Student’s t-test. (∗) P < 0.05; (∗∗) P < 0.01.
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in CtsB−/−S−/− tumors compared with wild-type lesions
(Fig. 4D). No alterations were detected in CtsB+/−S+/− tu-
mors (Supplemental Fig. S3A–C), indicating that com-
plete ablation of both CtsB and CtsS is necessary to
trigger the increase in TAM numbers and the up-regula-
tion of CtsZ. Consistent with this finding, tumor invasion
in CtsB+/−S+/− mice was significantly reduced compared
with CtsB−/−S−/− animals (Supplemental Fig. 1E). We
found that the accumulation of macrophages at the mar-
gins ofCtsB−/−S−/− tumors correlateswith their increased
invasive properties (Fig. 4E).Whilewild-type tumors accu-
mulate TAMs in the intermediate invasive stage (IC1),
Figure 4. Macrophages expressing high levels of CtsZ infiltrate CtsB−/−S−/− tumors. (A) CtsZ is highly expressed in CtsB−/−S−/− RT2
tumors, and these tumors also show elevatedmacrophage numbers. Antibodies against CtsZ (red) and Iba1, amacrophage-specific marker
(green), were used to identify cells expressing CtsZ and the presence of TAMs in wild-type RT2 andCtsB−/−S−/−RT2 tumors. CtsZ+ mac-
rophages are particularly concentrated in the invasive edge ofCtsB−/−S−/−RT2 tumors (evident in the lower images in the bottom panels).
(B) Quantification of CtsZ+ cells in wild-type RT2 (n = 62) andCtsB−/−S−/−RT2 (n = 33) tumors relative to the total number of DAPI+ cells
showed a significant increase in CtsB−/−S−/− RT2 tumors. (C ) Quantification of Iba+ TAMs in wild-type RT2 (n = 108) and CtsB−/−S−/−
RT2 (n = 28) tumors relative to the total number of DAPI+ cells showed a significant increase in TAMs in CtsB−/−S−/− RT2 tumors. (D)
mRNA expression of the macrophage marker Cd68 was determined by qPCR analysis of wild-type RT2 (n = 4) and CtsB−/−S−/− RT2
(n = 6) whole tumors and revealed a significant increase in expression inCtsB−/−S−/−RT2mice, consistent with the results inC. (E) Graph
showing the macrophage content within and at the margin of individual tumors from wild-type RT2 and CtsB−/−S−/− RT2 mice, as
determined by Iba1+ staining and according to each tumor invasive grade: encapsulated, IC1, or IC2 (as specified in Fig. 1E). (F ) Low-
magnification images of wild-type RT2 and CtsB−/−S−/− RT2 tumors stained with the macrophage-specific marker Iba1 (green) or hema-
toxylin and eosin (H&E), identifying the accumulation of TAMs at the margin of invasive CtsB−/−S−/− tumors compared with wild-type
invasive tumors. (G,H) mRNA expression of the chemoattractants Csf-1 (G) and Ccl5 (H) was determined by qPCR analysis of wild-type
RT2 (n = 4–5) andCtsB−/−S−/− RT2 (n = 5) whole tumors, which revealed a significant increase in expression of both genes inCtsB−/−S−/−
RT2mice.mRNAexpression determined by qPCRwas normalized toUbiquitinC for each sample inD,G, andH. The graphs showmean
± SEM. Statistical significance was calculated by unpaired two-tailed Student’s t-test. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001. Bars: A, 50
µm; F, 200 µm.
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CtsB−/−S−/− IC1 tumors show higher macrophage num-
bers, a feature that is maintained in the most invasive
IC2 lesions (Fig. 4E, F).
To investigate howCtsB−/−S−/− tumors evoke compen-
satory mechanisms to recruit macrophages, we examined
the mRNA expression levels of a panel of cytokines and
chemokines involved in myeloid cell recruitment (Ben-
Baruch 2006; Mantovani et al. 2010). We analyzed the
expression of Csf-1, Ccl2, Ccl5, Cxcl2, Cxcl14, Cxcl15,
and Vegf-a in wild-type, CtsB−/−S−/,− and CtsB+/−S+/− tu-
mors (Fig. 4G,H; Supplemental Fig. S3D–F). Interestingly,
we found that expression of Csf-1 and Ccl5, two well-
described monocyte/macrophage chemoattractants (Rob-
inson et al. 2003; Hamilton 2008), was significantly
increased specifically in CtsB−/−S−/− tumors, while the
other chemokines analyzed did not change significantly.
Together, these results establish a critical role for
TAMs in providing high levels of CtsZ in the microenvi-
ronment of CtsB−/−S−/− tumors. TAM accumulation cor-
relates with the increased invasiveness of CtsB−/−S−/−
tumors and up-regulation of specific factors involved in
macrophage recruitment, suggesting critical alterations
to the TME in CtsB−/−S−/− animals to mobilize these
cells. Given the frequent association between TAMs and
tumor invasion (Gocheva et al. 2010b; Qian and Pollard
2010), this may represent a compensatory mechanism to
overcome the combined loss of CtsB and CtsS, resulting
in the promotion of invasion at later stages of PanNET
malignancy.
Deletion of CtsZ in CtsB−/−S−/− RT2 mice decreases
tumor invasion and reduces TAM recruitment
To determinewhether the observedCtsZ up-regulation in
CtsB−/−S−/− tumors contributes functionally to enhanced
malignancy, we generated CtsB+/−S+/−Z+/− RT2 and
CtsB−/−S−/−Z−/− RT2 animals and assessed the conse-
quences of deleting these three proteases on multiple tu-
morigenic processes (Table 1). Analysis of cumulative
tumor volume changes in the triple-knockout RT2 mice
showed a 58% reduction in tumor burden and a 53%
decrease in tumor number compared with wild-type
RT2 animals (Fig. 5A,B). These observations are in accor-
dance with our results above that deletion of multiple
cathepsins does not lead to additive effects on tumor
growth. As observed for the combined deletion of CtsB
andCtsS, heterozygous deletion revealed effects on tumor
burden and number comparable with that of the complete
removal of all three cathepsins (Table 1; Supplemental
Fig. S4A,B).
Analysis of tumor grade in CtsB−/−S−/−Z−/− RT2 ani-
mals revealed a significant reduction in the incidence of
invasive carcinomas compared with CtsB−/−S−/− RT2
mice (Fig. 5C; Supplemental Fig. S4C), thus support-
ing our hypothesis that CtsZ mediates the invasive
phenotype observed in CtsB−/−S−/− RT2 animals.
Quantitation of cleaved caspase-3-positive (CC3+) cells
demonstrated a 3.8-fold and 5.7-fold increase in apoptosis
in CtsB−/−S−/−Z−/− tumors compared with wild-type and
CtsB−/−S−/− tumors, respectively (Fig. 5D; Supplemental
Figs. S1D, S4D). Cell proliferation in CtsB−/−S−/−Z−/−
and CtsB+/−S+/−Z+/− tumors was significantly reduced
compared with wild-type RT2 (Fig. 5E; Supplemental
Fig. S4E), although no further decrease was observed com-
pared with CtsB−/−S−/− lesions (Table 1). Vascularization
was also impaired in CtsB−/−S−/−Z−/− tumors compared
with either wild-type lesions (Fig. 5F; Supplemental Fig.
S4F) or CtsB−/−S−/− lesions (Table 1).
We next askedwhether the diminished invasive proper-
ties of CtsB−/−S−/−Z−/− tumors correlated with a change
in TAM numbers and performed staining of Iba1+ macro-
phages in the different genotypes analyzed in this study.
Indeed, the increase in TAMs observed in CtsB−/−S−/−
end-stage lesions was reversed inCtsB−/−S−/−Z−/− tumors
(Fig. 5G; Supplemental Fig. S4G). Expression of the che-
moattractant factors Ccl5 and Csf-1 was similar in
CtsB−/−S−/−Z−/− tumors and CtsB−/−S−/− tumors, while
CtsZ−/− RT2 tumors, which are poorly invasive and
show reduced TAM numbers (Akkari et al. 2014), did
not show significant changes in Ccl5 and Csf-1 levels
(Supplemental Fig. S4H,I). These results suggest that
the reduced TAM numbers in the triple-knockout mice
is a consequence specifically of CtsZ deletion, resulting
in impaired BMDM recruitment and reduced tumor
invasion.
Discussion
Our results show that functional compensation occurs
when multiple cathepsin proteases are targeted in Pan-
NETs. Interestingly, this occurs in a stage-specific man-
ner. Significant synergistic effects were observed early in
the tumorigenic process, where the simultaneous deletion
of bothCtsB andCtsS led to a 60%reduction in angiogenic
switching. This was the most pronounced effect observed
at this early stage inmultistage RT2 tumorigenesis for any
of the cathepsin knockouts previously reported (Table 1).
However, at end stage, no additive anti-tumorigenic ef-
fects were evident. There was no difference in prolifera-
tion, apoptosis or angiogenesis in CtsB−/−S−/− tumors
when compared with single-knockout animals. Further-
more, the invasive capacity of the CtsB−/−S−/− lesions
was actually comparablewithwild-type tumors, revealing
adaptive compensatorymechanisms counteracting loss of
both cathepsins via macrophage-derived CtsZ.
Interestingly, up-regulation of CtsZ also occurs
in CtsB−/− PyMT mammary tumors, specifically at the
cancer cell surface (Vasiljeva et al. 2006; Sevenich et al.
2010). However, in our study, compensation by CtsZ
was observed only whenmultiple cathepsins were deleted
and was largely mediated by accumulation of macrophag-
es in the tumor microenvironment. The increased num-
ber of TAMs at the tumor margin is potentially a result
of elevated expression of the chemoattractive factors
Csf-1 and Ccl5, associated with the enhanced capacity
of macrophages to respond to these signals via increased
expression of CtsZ. Thus, in the absence of CtsB and
CtsS, the ability to degrade ECM components that favors
tumor invasiveness may be compromised, and the
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recruitment of TAMs expressing and secreting high levels
of CtsZ provides an alternative mode of tumor invasion.
Tumor cell-derived CtsZ modulates migration and in-
vasion in a proteolytically independent manner in the
RT2 PanNET model (Akkari et al. 2014). Whether the
proinvasive role of TAM-derived CtsZ requires its car-
boxypeptidase activity remains to be elucidated. This is
currently challenging to address due to limited options
Figure 5. Deletion of CtsZ in CtsB−/−S−/− RT2 animals reduces macrophage infiltration and tumor invasion. (A) Graph depicting the
cumulative tumor burden, represented as the sum of the volumes of all tumors per mouse, in wild-type RT2 and CtsB−/−S−/−Z−/− RT2
animals at the 13.5-wk endpoint. Numbers of mice per group were as follows: wild-type RT2, n = 57; CtsB−/−S−/−Z−/− RT2, n = 14. (B)
Graph depicting the average number of tumors per mouse in wild-type RT2 and CtsB−/−S−/−Z−/− RT2 animals at 13.5 wk. The following
numbers of animals were analyzed per group: wild-type RT2, n = 58; CtsB−/−S−/−Z−/− RT2, n = 18. (C ) Graph showing the proportions of
encapsulated, microinvasive, and invasive carcinomas in CtsB−/−S−/− RT2 and CtsB−/−S−/−Z−/− RT2 mice at 13.5 wk. The following
number of mice were analyzed: CtsB−/−S−/− RT2, 14 mice, 68 tumors; CtsB−/−S−/−Z−/− RT2, 13 mice, 32 tumors. (D) Quantitation of
cleaved caspase-3 (CC3) staining in wild-type RT2 and CtsB−/−S−/−Z−/− RT2 tumors relative to the total number of DAPI+ cells revealed
a significant 3.6-fold increase in apoptosis in tumors deficient for CtsB, CtsS, and CtsZ. Tumors from 11 wild-type RT2 and seven
CtsB−/−S−/−Z−/− RT2 mice were analyzed. (E) Quantitation of Ki67 staining in wild-type RT2 (n = 5) and CtsB−/−S−/−Z−/− RT2 (n = 7) tu-
mors relative to the total number of DAPI+ cells. This revealed a 53% decrease in cell proliferation in tumors simultaneously deficient for
CtsB,CtsS, andCtsZ. (F ) Quantification of CD31+ endothelial cells in wild-type RT2 (n = 4) andCtsB−/−S−/−Z−/− RT2 (n = 10) tumors rel-
ative to the total number of DAPI+ cells, as determined by immunostaining of tissue sections. This analysis revealed a significant decrease
in tumor vascularization in CtsB−/−S−/−Z−/− RT2 mice. (G) Quantification of Iba+ macrophages in wild-type RT2 (n = 108), CtsB−/−S−/−
RT2 (n = 28), andCtsB−/−S−/−Z−/−RT2 (n = 14) tumors relative to the total number of DAPI+ cells. This analysis revealed that the increase
in TAM numbers observed in CtsB−/−S−/− RT2 tumors is reversed when CtsZ is deleted in these tumors.
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available to specifically target the catalytic activity of
CtsZ. In light of our recent results reporting the interac-
tion of macrophage-secreted CtsZ with the cancer cell
surface via integrins (Akkari et al. 2014), we infer that pro-
teolysis may not be strictly necessary for CtsZ-dependent
invasion inCtsB−/−S−/− tumors. These results thus under-
score the plasticity of adaptive behavior that tumors
exhibit when rendered deficient in critical mediators
of malignancy using tumor cell-intrinsic and/or cell-
extrinsic mechanisms.
Expression of a subset of MMPs is also altered in
CtsB−/−S−/− tumors. Previous reports suggest a mecha-
nism through which resistance to MMP inhibitors in-
volves elevated cathepsin activity, dependent on a
change in the abundance of inflammatory cells supplying
these proteases (Shchors et al. 2013). Thus, our data share
parallels with these results and show that deletion ofmul-
tiple cathepsin proteases can conversely alter MMP ex-
pression, possibly via perturbation of the protease web.
However, we infer that theseMMP expression changes ul-
timately have limited functional roles to compensate for
the loss ofCtsB andCtsS, as further deletion ofCtsZ fully
reverts the invasive phenotype of CtsB−/−S−/− tumors.
While several studies report the pleiotropic roles of
MMPs and cathepsins in promoting tumor progression in
different types of cancer (Coussens et al. 2002; Mohamed
and Sloane 2006), certain members of these protease clas-
ses also display tumor-suppressive functions (Dufour and
Overall 2013; Olson and Joyce 2015). For instance, CtsL
deletion enhances skin carcinogenesis in the K14-HPV16
and DMBA/TPA mouse models (Dennemarker et al.
2010; Benavides et al. 2012), and theproteaseMMP8exerts
anti-metastatic activity in the MDA-MB-231 breast can-
cermodel (Soria-Valles et al. 2014). Themultifaceted roles
of MMPs as enhancers or inhibitors of tumorigenesis
(Dufour and Overall 2013) can partly explain the failure
of broad-spectrummolecules targeting this protease fami-
ly and highlight the need for tissue-dependent, stage-
specific analysis of protease functions prior to using
pan-family inhibitors. In the RT2 PanNET model, all up-
regulated cathepsins have been characterized as protu-
morigenic, with the exception of CtsC, which had no ef-
fect when deleted (Gocheva et al. 2006, 2010b; Akkari
et al. 2014).
Our finding that CtsZ is up-regulated in response to the
simultaneous deletion of CtsB and CtsS has potential
translational implications in considering cathepsin inhib-
itors for the treatment of cancer patients. Our data would
argue that selective inhibitors directed against specific
subsets of cathepsins might lead to compensation by
untargeted family members or other protease classes
and therefore may not ultimately be as effective as
broad-spectrum inhibitors that target the entire family.
Indeed, treatment of RT2 mice with pan-cathepsin inhib-
itors (e.g., JPM-OEt and VBY-825) results in a pronounced
reduction in multiple hallmarks of cancer, including tu-
mor growth, vascularity, and invasion (Joyce et al. 2004;
Elie et al. 2010), supporting this viewpoint. Moreover,
we report that heterozygous deletion of multiple cathep-
sins results in impaired tumor growth to an extent similar
to complete ablation yet does not lead to compensatory
alterations in the expression of other proteases. The accu-
mulation of TAMs evident in CtsB−/−S−/− tumors is not
observed in heterozygous lesions, and the increase in
Ccl5 and Csf-1 chemoattractants or CtsZ up-regulation
is also not observed. Consequently, this failure to
develop adaptive compensatory mechanisms is associat-
ed with less invasive lesions in CtsB+/−S+/− animals
compared with CtsB−/−S−/− mice. This could indicate
that partial blockade of cathepsins (as achieved by phar-
macological inhibitors) may be preferable to their com-
plete ablation.
In sum, perturbations to the protease web have the po-
tential to result in unexpected phenotypes that may not
only complicate interpretation of genetic analyses but
also interfere with the efficacy of selectively targeted pro-
tease inhibitors. The selective pressure to recalibrate the
protease web may be particularly evident in cancer given
the heterogeneity and plasticity of the tumor micro-
environment, which would facilitate rapid adaptive com-
pensation. These points should therefore be carefully
considered when therapeutically targeting protease fami-
lies in cancer.
Materials and methods
Mouse strains
The generation of RT2 (Hanahan 1985), CtsB-null (Halangk et al.
2000), CtsS-null (Shi et al. 1999), and CtsZ-null (Sevenich et al.
2010) mice and each of the single constitutive cathepsin-null
RT2 lines (Gocheva et al. 2006; Akkari et al. 2014) has been re-
ported previously. β-Actin GFP transgenic mice in the C57BL/6
background (Okabe et al. 1997) were purchased from Jackson Lab-
oratories. All animal studies were performed using protocols ap-
proved by the Animal Care Committee at Memorial Sloan
Kettering Cancer Center.
Tissue processing and immunostaining
For angiogenic switching analyses, RT2 mice were sacrificed at
10.5 wk of age by heart perfusion with 10 mL of PBS under anes-
thesia. The pancreas was then removed and minced gently with
scissors. Following a collagenase P (Sigma) digestion, the number
of angiogenic islets, distinguishable by their red and hemorrhagic
appearance, was counted under a dissecting microscope, as previ-
ously described (Parangi et al. 1995). Angiogenic switching ability
was determined by comparing the average of the sum of all angio-
genic islets per mouse between the different genotypes.
Tumor volume and number were determined at 13.5 wk of age,
and RT2 mice were sacrificed by heart perfusion with PBS fol-
lowed by 10% zinc-buffered formalin. Tissues were removed,
placed in 30% sucrose overnight and embedded in OCT (Tis-
sue-Tek). The dimensions of the tumors were measured as previ-
ously described (Joyce et al. 2004). Tumor burdenwas represented
as the sum of the volumes of all tumors per mouse.
For the phenotypic characterization of the tumors, frozen sec-
tions (10 µm thick) were cut on a cryostat and analyzed by immu-
nostaining. Immunofluorescence staining on frozen sections
from RT2 animals was performed after sections were dried for
30min at room temperature, rehydrated in PBS for 10 min, prein-
cubated with 1× PNB blocking buffer (PerkinElmer Life Sciences)
for 1 h, and then incubated with the primary antibody of interest
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overnight at 4°C. The following anti-mouse antibodieswere used:
rat CD31 (1:200; BD Pharmingen), goat CtsZ (1:1000; R&D Sys-
tems), rat CD68 (1:1000; Serotec), and rabbit Iba-1 (1:1000;
Wako). The corresponding secondary antibodies were used at a
1:500 dilution and incubated for 1 h at room temperature. DAPI
(1:5000; Invitrogen) was used to label the nuclei, and the slides
were mounted in ProLong Gold mounting medium (Invitrogen).
The tissues were observed under a Carl Zeiss Axioimager Z1 mi-
croscope, and images were acquired with Axiovision using an
Apotome (Zeiss) or with TissueFAXS (TissueGnostics).
To analyze proliferation rates in the tumors, slideswere stained
with a rabbit anti-mouse Ki67 antibody (1:200; Vector Laborato-
ries), and the numbers of Ki67+ cells relative to total cell number
were determined using TissueQuest. For apoptosis analysis, the
frozen tissues were stained using rabbit anti-mouse CC3 (1:500;
Cell Signaling Technology). The number of CC3+ cellswas count-
ed using TissueQuest, and the percentage of cell death was calcu-
lated as the percentage of the total cells per tumor. For invasion
grading, hematoxylin and eosin (H&E) staining was performed,
and the lesions were graded as previously described (Lopez and
Hanahan 2002) following a double-blind protocol and indepen-
dently assessed by two investigators (L. Akkari/V. Gocheva and
J.A. Joyce). The numbers of tumors and mice analyzed are speci-
fied in the figure legends. In order to include the quantitation of
peripheral macrophages in Figure 4E, a dilated peritumoral region
500 μm in diameter was used to calculate the total Iba1+ area and
the total DAPI+ area within this region. For analysis of angiogen-
esis, tumors from13.5-wk-old RT2mice from the indicated geno-
types were stained with a rat anti-CD31 antibody, and the vessel
areawas calculated as the ratio of CD31+ endothelial cells divided
by the DAPI+ tumor area as detected by pixel intensity and ana-
lyzed using Volocity imaging software.
Flow cytometry and sorting
Wild-type and CtsB−/−S−/− RT2 tumors were isolated and pro-
cessed for fluorescence-activated cell sorting as previously de-
scribed (Pyonteck et al. 2012) using the following antibodies:
CD31-FITC (1:100; BD Pharmingen), CD45-PE (1:200; BD Phar-
mingen), anti-F4/80-APC (1:100; Serotec), and DAPI for dead
cell exclusion. The cells were sorted on a fluorescence-activated
cell sorting Aria flow cytometer (BD Biosciences), and fractions
were collected: a mixed population of live cells (DAPI−), purified
tumor cells (DAPI− CD31− CD45− F4/80−), and macrophages
(DAPI− CD31− CD45+ F4/80+).
Preparation of cell lysates
To obtain whole-cell protein lysates, BMDMs were washed in
cold 1× PBS once and then lysed in RIPA buffer containing prote-
ase and phosphatase inhibitors (Thermo Fisher Scientific). The
crude lysates were centrifuged at 13,000 rpm for 12 min, and su-
pernatants containing intracellular proteins were collected for
downstream analyses. The NE-PER nuclear and cytoplasmic ex-
traction kit (ThermoFisher Scientific) was used to isolate nuclear
and cytoplasmic fractions from RT2 BMDMs (Fig. 3C) according
to the manufacturer’s instructions.
RNA isolation and quantitative RT–PCR
RNA was isolated with Trizol and DNase-treated, and 1 µg
of RNA was used for cDNA synthesis using a high-capacity
cDNA reverse transcription kit (Applied Biosystems). TaqMan
probes (Applied Biosystems) were used for quantifying expres-
sion of CtsB (Mm00514439_m1), CtsZ (Mm00517697_m1),
CtsC (Mm00515580_m1), CtsH (Mm00514455_m1), CtsS
(Mm00457902_m1), CtsL (Mm00515597_m1), CstC
(Mm00438347_m1), Mmp2 (Mm00439502_m1), Mmp3
(Mm00440295_m1), Mmp9 (Mm00600163_m1), Mmp12
(Mm00500554_m1), Mmp13 (Mm00439491_m1), Mmp14
(Mm00485054_m1), Mmp15 (Mm00485062_m1), Csf-1
(Mm00432688_m1), Ccl2 (Mm00441242_m1), Ccl5
(Mm01302428_m1), Cxcl2 (Mm00436450_m1), Cxcl14
(Mm00444699_m1), Cxcl15 (Mm00469712_m1), and Vegf-a
(Mm00437304_m1).Ubc (Mm02525934_g1) was used as a house-
keeping control.
Promoter analysis
Transcription factor-binding site predictions for the mouse ge-
nome (mm9) were downloaded from the SwissRegulon portal
(http://swissregulon.unibas.ch/data/mm9/mm9_sites.gff.gz) (Pach-
kov et al. 2007). TFMswere tabulated 2 kb upstreamof and down-
stream from the transcription start site for CtsB, CtsC, CtsH,
CtsL, CtsS, and CtsZ. Promoters in Figure 3B were drawn using
the “ggbio” package in R (Yin et al. 2012).
Statistical analysis
Data are presented throughout as mean and SEM. Results were
analyzed by unpaired two-tailed Student’s t-tests unless other-
wise noted and were considered statistically significant if P <
0.05. For the invasion analysis, a cumulative logit model (McCul-
lagh 1980) with generalized estimating equations to correct for
correlations within individual mice was used to compare the dis-
tribution of tumor types in the control group with the distribu-
tion of tumors in the experimental groups.
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Supplemental Figure 1: Analysis of tumor burden, number, proliferation, 
apoptosis, invasion and vascularization in CtsB+/-S+/- RT2 and CtsB-/-S-/- RT2 
mice. 
(A) Cumulative tumor volume calculated for 13.5w WT RT2 and CtsB-/-S-/- RT2 
mice  (as presented in Figure 1A) are plotted here with analysis of CtsB+/-S+/- RT2 
tumors (n=27), which showed a similar phenotype to that of the cathepsin double 
knockouts. 
(B) The average number of tumors per mouse in 13.5w WT RT2 and CtsB-/-S-/- 
RT2 animals (as presented in Figure 1B) are plotted here with the addition of 
CtsB+/-S+/- RT2 animals (n=37), which showed a similar phenotype to that of the 
cathepsin double knockouts.  
(C) Quantitation of Ki67 staining in WT and CtsB-/-S-/- RT2 tumors (as presented 
in Figure 1D) are plotted here with analysis of proliferation in CtsB+/-S+/- RT2 
tumors. A significant decrease in cell proliferation was only observed for the 
double knockout tumors and not in the heterozygous lesions. Tumors from 5 WT 
RT2, 4 CtsB+/-S+/- RT2, and 11 CtsB-/-S-/- RT2 mice were analyzed. 
(D) Quantitation of cleaved caspase-3 (CC3) staining in WT, CtsB+/-S+/- and CtsB-
/-S-/- RT2 tumors revealed no significant changes between genotypes. Tumors 
from 11 WT RT2, 5 CtsB+/-S+/- RT2, and 10 CtsB-/-S-/- RT2 mice were analyzed. 
(E) Graph showing the proportions of encapsulated, microinvasive and invasive 
carcinomas in WT RT2 and CtsB-/-S-/- RT2 mice at 13.5w (as presented in Figure 
1E) are plotted here with analysis of CtsB+/-S+/- RT2 mice. The following number 
of tumors were graded: WT RT2: 18 mice, 97 tumors; CtsB+/-S+/- RT2: 17 mice, 
99 tumors; CtsB-/-S-/- RT2: 14 mice, 68 tumors. 
(F) Representative images of WT RT2 or CtsB-/-S-/- RT2 tumors stained with the 
endothelial cell marker CD31 (red). The nuclei were counterstained with DAPI 
(blue).  
(G) Detailed angiogenesis analysis did not reveal any significant difference in 
various blood vessel parameters between WT RT2 and CtsB-/-S-/- RT2 mice. 
Images of tumors stained for CD31 were acquired and analyzed by manually 
tracing the vessels using Volocity imaging software. Five random fields per tumor 
were analyzed for five mice per group. Microvascular density was calculated by 
dividing the number of line segments by the tumor area (top left). Vessel 
branching is represented by the ratio of line segments to the total vessel length 
(top right). The average vessel length is the total vessel length divided by the 
number of vessels (bottom left). Length density is calculated by dividing the total 
vessel length by the tumor area (bottom right).  
Graphs show mean ± s.e.m. Statistical significance was calculated by unpaired 
two-tailed Student’s t-test (A-D, G); or using a cumulative logit model with 
generalized estimating equations to correct for correlations within individual mice 
(E) (n.s.) nonsignificant, *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars in (F): 50 
µm.  
 
Supplemental Figure 2: Expression analyses of multiple proteases in 
CtsB+/-S+/- and CtsB-/-S-/- tumors. 
(A) mRNA expression levels of CtsZ, Mmp3, Mmp9, and Mmp13 was determined 
by qPCR in WT RT2 and CtsB-/-S-/- RT2 tumors (end-stage, 13.5w) as depicted in 
Figure 2A, and are plotted here with analysis of CtsB+/-S+/- RT2 tumors. Other 
than Mmp13 mRNA, no significant differences in mRNA expression were 
observed in the heterozygous CtsB+/-S+/- RT2 tumors. 3-8 independent tumors 
per genotype were used for analysis.  
(B) mRNA expression levels of CtsB, CtsC, CtsH, CtsL, CtsS, Cystatin (Cst)C, 
Mmp2, Mmp12, Mmp14, and Mmp15 was determined by qPCR in WT RT2, 
CtsB-/-S-/- RT2 and CtsB+/-S+/- RT2 13.5w tumors. This analysis revealed no 
significant differences between genotypes with the exception of increased 
Mmp15 expression in CtsB-/-S-/- RT2 tumors compared to WT RT2 tumors. 3-8 
independent tumors per genotype were used for analysis.  
(C) mRNA expression levels of Mmp3, Mmp9 and Mmp13 (3 out of the 4 
significantly altered genes characterized in whole tumors from WT RT2 and CtsB-
/-S-/- RT2 end-stage mice, see Figure 2A) was determined by qPCR analysis of 
bone marrow-derived macrophages (BMDMs) prepared from tumor-bearing WT 
RT2 and CtsB-/-S-/- RT2 animals. Analysis revealed a significant decrease in 
Mmp3 expression, while no significant changes in expression were detected for 
Mmp9 and Mmp13. 3-8 independent replicates were analyzed. 
(D) Tumors from WT RT2 or CtsB-/-S-/- RT2 mice were sorted into a mixed 
population of live cells (DAPI-), cancer cells (CD45- CD31- F4/80-) or tumor-
associated macrophages (TAMs) (CD45+ F4/80+ CD31-). Expression of Mmp3, 
Mmp9 and Mmp13 mRNA was determined by qPCR, and the level is depicted 
relative to the live cell fraction. No significant changes were observed. 3-5 
independent sorted samples were analyzed. 
mRNA expression determined by qPCR was normalized to Ubiquitin C for each 
sample in all panels presented. Graphs show mean ± s.e.m. Statistical 
significance was calculated by unpaired two-tailed Student’s t-test; (n.s.) 
nonsignificant, *P < 0.05, **P < 0.01, ***P < 0.001.  
 
Supplemental Figure 3: Macrophage numbers and chemokine gene 
expression are not altered in CtsB+/-S+/- tumors. 
(A) Quantification of CtsZ+ cells in WT RT2 (n=62) and CtsB-/-S-/- RT2 (n=33) 
tumors (as shown in Figure 4B) are plotted here with analysis of CtsB+/-S+/- RT2 
(n=32) tumors, relative to the total number of DAPI+ cells. This analysis showed 
no changes in CtsZ+ cell numbers in CtsB+/-S+/- RT2 tumors. 
(B) Quantification of Iba+ macrophages in WT RT2 (n=108) and CtsB-/-S-/- RT2 
(n=28) tumors as depicted in Figure 4C were plotted together with analysis of 
CtsB+/-S+/- RT2 tumors (n=50) relative to the total number of DAPI+ cells. This 
analysis showed no changes in Iba1+ cells in CtsB+/-S+/- RT2 tumors. 
(C) mRNA expression of the macrophage marker Cd68 was determined by 
qPCR analysis of WT RT2 (n=4) and CtsB-/-S-/-RT2 (n=6) as depicted in Figure 
4D and plotted together with analysis of CtsB+/-S+/- RT2 (n=3) tumors. This 
analysis showed no changes in Cd68 expression in CtsB+/-S+/- RT2 tumors, 
consistent with the results in (B).  
(D-F) mRNA expression of the chemoattractants Csf-1 (D), Ccl5 (E), Ccl2, Cxcl2, 
Cxcl14, Cxcl15 and Vegf-a (F) was determined by qPCR analysis of WT RT2, 
CtsB-/-S-/- RT2, and CtsB-/-S-/- RT2 whole tumors, and revealed a significant 
increase in Csf-1 and Ccl5 expression in CtsB-/-S-/- RT2 mice compared to their 
WT counterparts. All comparisons in (F) were not significant. 3-5 independent 
tumors per genotype were used for analysis.  
mRNA expression determined by qPCR was normalized to Ubiquitin C for each 
sample in C-F. Graphs show mean ± s.e.m. Statistical significance was 
calculated by unpaired two-tailed Student’s t-test; (n.s.) nonsignificant, *P < 0.05, 
**P < 0.01, ***P < 0.001.  
 
Supplemental Figure 4: Characterization of tumorigenic phenotypes in 
CtsB+/-S+/-Z+/- RT2 and CtsB-/-S-/-Z-/- RT2 mice.  
(A) CtsB-/-S-/-Z-/- RT2 and CtsB+/-S+/-Z+/- RT2 animals were generated and 
cumulative tumor burden, represented as the sum of the volumes of all tumors 
per mouse, was calculated for 13.5w WT RT2, CtsB+/-S+/-Z+/- RT2 and CtsB-/-S-/-Z-
/- RT2 mice (n=57, n=18, n=14 mice per group, respectively). 
(B) Graph depicting the average number of tumors per mouse in WT RT2, CtsB+/-
S+/-Z+/- RT2 and CtsB-/-S-/-Z-/- RT2 animals at the 13.5-week endpoint. The 
following numbers of animals were analyzed per group: WT RT2 (n= 58), CtsB+/-
S+/-Z+/- RT2 (n= 20), CtsB-/-S-/-Z-/- RT2 (n= 18). 
(C) Graph showing the proportions of encapsulated, microinvasive and invasive 
carcinomas in CtsB+/-S+/- RT2, CtsB-/-S-/- RT2, CtsB+/-S+/-Z+/- RT2 and CtsB-/-S-/-Z-/- 
RT2 mice at 13.5w. The following number of mice were analyzed: WT RT2: 18 
mice, 97 tumors; CtsB+/-S+/- RT2: 16 mice, 98 tumors; CtsB-/-S-/- RT2: 14 mice, 68 
tumors; CtsB+/-S+/-Z+/- RT2: 14 mice, 49 tumors; CtsB-/-S-/-Z-/- RT2: 13 mice, 32 
tumors. 
(D) Quantitation of cleaved caspase-3 (CC3) staining in WT RT2, CtsB+/-S+/-Z+/- 
RT2, and CtsB-/-S-/-Z-/- RT2 tumors relative to the total number of DAPI+ cells 
revealed a significant 3.6-fold increase in apoptosis in tumors deficient for CtsB, 
CtsS and CtsZ and a 4.6-fold increase in tumors heterogygous for the three 
cathepsins. Tumors from 11 WT RT2, 5 CtsB+/-S+/-Z+/- RT2, and 7 CtsB-/-S-/-Z-/- 
RT2 mice were analyzed. 
(E) Quantitation of Ki67+ cells in WT RT2 (n= 5), CtsB+/-S+/-Z+/- RT2 (n= 5) and 
CtsB-/-S-/-Z-/- RT2 (n= 7) tumors relative to the total number of DAPI+ cells. This 
analysis revealed a 53% decrease in cell proliferation in tumors deficient for 
CtsB, CtsS and CtsZ in combination. 
(F) Quantification of CD31+ endothelial cells in WT RT2 (n=4), CtsB+/-S+/-Z+/- RT2 
(n=6), CtsB-/-S-/-Z-/- RT2 (n=10) tumors relative to the total number of DAPI+ cells, 
as determined by immunostaining of tissue sections. This analysis revealed a 
significant decrease in tumor vascularization specifically in CtsB-/-S-/-Z-/- RT2 
mice.  
(G) Quantification of Iba+ macrophages in WT RT2 (n=108), CtsB-/-S-/- RT2 
(n=28), CtsB+/-S+/- RT2 (n=50), CtsB-/-S-/-Z-/- RT2 (n=14), CtsB+/-S+/-Z+/- RT2 (n=6), 
and CtsZ-/- RT2 (n=41) tumors relative to the total number of DAPI+ cells. This 
analysis revealed that the increase in TAM numbers observed in CtsB-/-S-/- RT2 
tumors is lost when CtsZ is deleted in these tumors. 
(H-I) mRNA expression of the chemoattractants Csf-1 (H) and Ccl5 (I) was 
determined by qPCR analysis of WT RT2 (n=5), CtsB-/-S-/- RT2 (n=5), CtsB-/-S-/-Z-
/- (n=4) and Cts-Z-/- (n=5) whole tumors, which revealed a significant increase in 
expression of both genes in CtsB-/-S-/-Z-/- RT2 mice compared to WT tumors, and 
no changes in expression levels between CtsB-/-S-/- and CtsB-/-S-/-Z-/- lesions. 
mRNA expression determined by qPCR was normalized to Ubiquitin C for each 
sample in H-I. Graphs show mean + s.e.m. Statistical significance was calculated 
by unpaired two-tailed Student’s t-test (A, B, D-I), or using a cumulative logit 
model with generalized estimating equations to correct for correlations within 
individual mice (C); (n.s.) nonsignificant, *P < 0.05, **P < 0.01, ***P < 0.001. 
 
 !
These lists correspond to the venn diagram in Fig. 3A. The lists of transcription factor motifs (TFMs) are found in (1) the 
CtsZ promoter only, (2) CtsZ promoter and at least one other cathepsin family member (CtsB, CtsC, CtsH, CtsL, CtsS), or 
(3) absent in the CtsZ promoter and present in at least one of these other cathepsin family members. All TFM definitions 
can be found in the SwissRegulon database at: http://swissregulon.unibas.ch/data/mm9/mat_TF_associations.mm.
CtsZ Only (n=9) CtsZ or any other cathepsins (n=21) Any other cathepsin but not CtZ (n=83)
EN1%2C2.p2 DBP.p2 ADNP_IRX_SIX_ZHX.p2
FOXN1.p2 EBF1.p2 ARID5B.p2
GTF2A1%2C2.p2 ELK1%2C4_GABP{A%2CB1}.p3 BPTF.p2
HIF1A.p2 GTF2I.p2 CDX1%2C2%2C4.p2
HOX{A6%2CA7%2CB6%2CB7}.p2HIC1.p2 CRX.p2
NFKB1_REL_RELA.p2 KLF4.p3 EP300.p2
PAX5.p2 LMO2.p2 ETS1%2C2.p2
REST.p3 MAZ.p2 EVI1.p2
TBX4%2C5.p2 MTF1.p2 EWSR1
MYFfamily.p2 FEV.p2
NHLH1%2C2.p2 FOX{F1%2CF2%2CJ1}.p2
PATZ1.p2 FOXA2.p3
RXR{A%2CB%2CG}.p2 FOXD3.p2
SP1.p2 FOXO1%2C3%2C4.p2
SPI1.p2 GATA1..3.p2
SPZ1.p2 HAND1%2C2.p2
TCF4_dimer.p2 HNF4A_NR2F1%2C2.p2
TFAP2{A%2CC}.p2 MEF2{A%2CB%2CC%2CD}.p2
TFAP4.p2 MYOD1.p2
TFDP1.p2 MZF1.p2
ZNF148.p2 NKX3
POU5F1_SOX2{dimer}.p2
RREB1.p2
RUNX1..3.p2
ZBTB16.p2
ZNF384.p2
AIRE.p2
AR.p2
ELF1%2C2%2C4.p2
FOX{C1%2CC2}.p2
HOX{A5%2CB5}.p2
IKZF2.p2
KLF12.p2
MAFB.p2
MYB.p2
NFATC1..3.p2
SI1..3.p2
STAT2%2C4%2C6.p2
TLX2.p2
ALX1.p2
DMAP1_NCOR{1%2C2}_SMARC.p2
GFI1.p2
GLI1..3.p2
HES1.p2
HMGA1%2C2.p2
NR3C1.p2
PITX1..3.p2
SOX5.p2
SRY.p2
AHR_ARNT_ARNT2.p2
ATF2.p2
ATF4.p2
bHLH_family.p2
CEBPA%2CB_DDIT3.p2
EGR1..3.p2
FOSL2.p2
FOX{I1%2CJ2}.p2
HLF.p2
NFE2L2.p2
NFY{A%2CB%2CC}.p2
NR1H4.p2
PAX2.p2
PAX4.p2
POU1F1.p2
POU3F1..4.p2
PPARG.p2
RBPJ.p2
RXRA_VDR{dimer}.p2
SOX2.p2
SREBF1%2C2.p2
TEAD1.p2
TFAP2B.p2
TFCP2.p2
TFEB.p2
TP53.p2
ZFP161.p2
HOXA9_MEIS1.p2
LEF1_TCF7_TCF7L1%2C2.p2
NR5A1%2C2.p2
NR6A1.p2
PDX1.p2
SMAD1..7%2C9.p2
SPIB.p2
 Akkari, Gocheva et al, Supplemental Table 1
Any other cathepsin but not CtsZ (n=83)CtsZ only (n=9) CtsZ or any other cathepsin (n=21)
